期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 47, 期 6, 页码 421-429出版社
ELSEVIER
DOI: 10.1016/j.ijantimicag.2016.04.007
关键词
Tuberculosis; Mycobacterium tuberculosis; Efflux pump inhibitor; Verapamil; Reserpine; CCCP
资金
- Serious Infectious Diseases Special Foundation of China [2012ZX10003008002]
Resistance and tolerance to antituberculosis (anti-TB) drugs, especially the first-line drugs, has become a serious problem in anti-TB therapy. Efflux of antimicrobial agents via bacterial efflux pumps is one of the main reasons for drug resistance. Efflux pump inhibitors (EPIs) bind to efflux pumps to inhibit drug efflux and thus enhance the drug effect and reduce drug resistance. Studies on EPIs targeting the efflux pumps of Mycobacterium tuberculosis (Mtb) help to understand Mtb resistance and to identify the potential drug target and are of significance in guiding the development of new anti-TB drugs and optimal combinations. Currently, there are many potential EPIs under study, but none of them has been used clinically for anti-TB therapy. In this article, we will provide an overview on the current development of EPIs targeting the efflux pumps of Mtb and discuss their potential clinical applications. (C) 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据